Playback speed
10 seconds
ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation, Confirmation, and Cohort Expansion Study of Nemtabrutinib in Hematologic Malignancies"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Guilherme Perini
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Guilherme Perini
0 views
June 14, 2023
Comments 0
Login to view comments.
Click here to Login